DIAGNOSTIC AND CLASSIFICATION METHOD OF LEFT VENTRICULAR HYPERTROPHY Russian patent published in 2020 - IPC A61B5/00 A61B8/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to instrumental diagnostics in cardiology, and can be used for diagnosis of left ventricular hypertrophy and classification of its manifestations in individuals with obesity, excess or body weight deficiency. Myocardial mass is determined on an EchoCG test and an actual left ventricular myocardial mass index ALVMI. Patient's height and weight are determined. Body surface area (BSA) and body mass index (BMI) are calculated. If the patient has a BMI more than 25 kg/m² or less than 20 kg/m², the proper body weight (pBW) is determined according to the claimed formula. Further, the proper body surface area (pBSA) is determined by the claimed formula. pALVMI is determined by the ratio of the actual left ventricular myocardial weight to the "proper body surface area". Obtained values of the actual left ventricular mass index and the "adequate left ventricular mass index" are compared with the recommended upper limit values for the left ventricular myocardial mass index. If the upper limit of the norm is exceeded, both indices are used to determine the presence of left ventricular global thickening fraction manifest (LVGTF) - corresponds to the increased left ventricular myocardial mass regardless of the human complexion. If the upper limit of the norm is exceeded, only the "adequate myocardial mass index" is used to determine the presence of "latent LVGTF" - corresponds to the increased left ventricular myocardial mass in proportion to the body weight excess. If the upper limit of the norm is exceeded, only the actual myocardial mass index shows the presence of "relative LVGTF" - corresponds to the increased left ventricular myocardial weight for body weight below the norm. If both indices are found at the upper limit of normal or below, "absence of LVGTF" is determined.

EFFECT: method allows more differentiated approach to diagnosing left ventricular myocardial hypertrophy in individuals with pathological weight abnormalities and provides a basis for more in-depth analysis of the causes of its development.

1 cl, 1 tbl, 3 ex